Indacaterol | The First Once-daily Long-acting Beta2 Agonist for COPD | Alexandre Trifilieff | Buch | Milestones in Drug Therapy | HC runder Rücken kaschiert | VII | Englisch | 2013 | Springer Basel - encadernada, livro de bolso

Livro na base de dados desde 2014-09-14T13:56:16-03:00 (Sao Paulo)
Página de detalhes modificada pela última vez em 2023-12-18T08:29:41-03:00 (Sao Paulo)
Número ISBN/EAN: 9783034807081

Número ISBN - Ortografia alternativa:
3-0348-0708-2, 978-3-0348-0708-1
Ortografia alternativa e termos de pesquisa relacionados:
Autor do livro: alexandre, basel iii
Título do livro: acting first six, copd, milestones

Dados da editora

Autor: Alexandre Trifilieff
Título: Milestones in Drug Therapy; Indacaterol - The First Once-daily Long-acting Beta2 Agonist for COPD
Editora: Springer; Springer Basel
146 Páginas
Ano de publicação: 2013-11-27
Basel; CH
Impresso / Feito em
Peso: 3,613 kg
Língua: Inglês
106,99 € (DE)
109,99 € (AT)
118,00 CHF (CH)
POD
VII, 146 p. 41 illus., 21 illus. in color.

BB; Pharmacology/Toxicology; Hardcover, Softcover / Medizin/Pharmazie; Pharmakologie; Verstehen; Asthma; Beta-2-Agonists; Bronchitis; Bronchodilatator; Lung function; Pneumology/Respiratory System; Pharmacology; Pneumology; Lungen- und Bronchialheilkunde; EA

Chronic obstructive pulmonary disease (COPD) is a multi-component condition that results in increasingly limited airflow, usually associated with an abnormal inflammatory response of the lung. It constitutes a major public health burden worldwide, while only very few effective therapies are available.

This book provides a comprehensive overview of the development of Onbrez Breezhaler, a newly approved once-daily inhaled β2 agonist for the treatment of COPD. It reviews the current pharmacotherapy for COPD and discusses topics such as the chemical design and the pre-clinical pharmacology of the molecule, the early clinical development, the INHANCE study (which provides a successful example of the use of an adaptive design in the confirmatory setting) and the Phase III clinical efficacy study, as well as the history and performance of the Breezhaler device. Finally, a list of emerging targets is included that could well offer future treatment options for COPD.

Current Pharmacotherapy for COPD.- The preclinical pharmacology of indacaterol.- The design of the indacaterol molecule.- The early clinical development of Indacaterol.- INHANCE: An adaptive confirmatory study with dose selection at interim.- Phase III clinical efficacy studies – lung function.- Phase III Clinical Efficacy of Indacaterol.- Patient-centered Outcomes.- The history and performance of the Breezhaler device.- What does the future hold for the therapy of COPD?  

Chronic obstructive pulmonary disease (COPD) is a multi-component condition that results in increasingly limited airflow, usually associated with an abnormal inflammatory response of the lung. It constitutes a major public health burden worldwide, while only very few effective therapies are available.

This book provides a comprehensive overview of the development of Onbrez Breezhaler, a newly approved once-daily inhaled β2 agonist for the treatment of COPD. It reviews the current pharmacotherapy for COPD and discusses topics such as the chemical design and the pre-clinical pharmacology of the molecule, the early clinical development, the INHANCE study (which provides a successful example of the use of an adaptive design in the confirmatory setting) and the Phase III clinical efficacy study, as well as the history and performance of the Breezhaler device. Finally, a list of emerging targets is included that could well offer future treatment options for COPD.

Summarizes preclinical and clinical data

A valuable source of information for scientists and clinicians

Contemporary monograph on the pharmacotherapy of COPD

Includes supplementary material: sn.pub/extras